Mianzhi Zhao

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)

Qin Ning, Meifang Han, Yongtao Sun et al. · Journal of Hepatology · 2014 · 279 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B

Qing Xie, Huijuan Zhou, Xue–Fan Bai et al. · Clinical Infectious Diseases · 2014 · 85 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.

Joon Oh Park, Yin‐Hsun Feng, Yen‐Yang Chen et al. · Journal of Clinical Oncology · 2019 · 78 citations

Medicine, Oncology, Pharmacology +14

Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study

Meifang Han, Jiaji Jiang, Jinlin Hou et al. · Antiviral Therapy · 2015 · 53 citations

Pharmacy, Pharmacology, Pharmacotherapy +17